報價延遲最少15分鐘:2024/11/10 19:41 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.24 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.34/3.88
|
|
企業價值
1.39B
|
| 資產負債 |
|
每股賬面淨值
19.06
|
| 現金流量 |
|
現金流量率
0.20
|
| 損益表 |
|
收益
674.98M
|
|
每股收益
14.43
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/10 19:41 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |